Dr. Chamindra G. Laverty, MD

Dr. Laverty practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Laverty's NPI, 1538320395, was assigned on June 24, 2008. Dr. Laverty graduated from Drexel University College Of Medicine in 2006. Dr. Laverty's California license number on file is A101351.

Dr. Laverty's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Laverty's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Laverty is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Laverty to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laverty practices. Vendor and product names are available with a free account.

Neurology is Dr. Laverty's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Laverty is board certified in american board of electrodiagnostic medicine by the American Board of Electrodiagnostic Medicine. Dmand AI has Dr. Laverty's licenses on file in 3 states: California, Wisconsin and Pennsylvania.

Dmand AI lists carpal tunnel syndrome, fibromyalgia and chronic pain, hereditary polyneuropathy, lower back pain, muscle disease and neuropathy among the conditions Dr. Laverty treats.

CMS data shows 256 Medicare services from Dr. Laverty across 6 procedure codes in 2024, for 142 Medicare patients. Medicare paid $28,349 for them.

CMS counts 142 Medicare patients who saw Dr. Laverty in 2024. The largest group is 65 to 74, with 51 patients. 70% of them have high blood pressure, and 64% have high cholesterol. 35% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Laverty's median patient age at 44, with 53% women.

In 2024, Dr. Laverty wrote 159 Medicare Part D claims for 20 patients. 57% of them were for generic drugs. CMS names the drug for 127 of them, across 7 drugs with 11 or more claims each, at $955,214 in total drug cost. In 2023, CMS named 91 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Laverty for performance year 2024, reported as part of a group. Dr. Laverty accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Laverty, published from 2023 to 2025. 2024 was the busiest year, with 2. The most frequent topics are Muscular Dystrophy, Duchenne and Phenotype. Dr. Laverty's most frequent co-authors are Rakesh Bhattacharjee, MD, Stephen R. Braddock, MD and Barry J. Byrne, MD.

CMS Open Payments shows 354 general payments to Dr. Laverty from 25 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 81% of the total. Sarepta Therapeutics, Inc. paid the most, $465,447. It also lists 1 research payment totaling $3,231 in 2025.

Dmand AI lists 5 awards for Dr. Laverty, most recently Neurology Faculty Resident Teaching Award in 2014.

Dr. Laverty graduated from Drexel University College Of Medicine in 2006. Dr. Laverty is a member of AAN and World Muscle Society.

Dr. Laverty is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.